SHANGHAI--(BUSINESS WIRE)--The 3^rd Annual BioPartnering China conference, co-produced by TVG and the Zhangjiang Biotech Pharmaceutical Base, launched today at the Renaissance Shanghai Pudong Hotel. The conference attracts a global representation of industry leaders from China, Europe and the USA. For the 3^rd year running, BioPartnering China^TM (BPC) is proving to be an important venue for international life science executives to access the innovation and partnering opportunities represented in China’s rapidly-growing life science industry.

Today delegates had the opportunity to hear a keynote address offering insights into China's emerging market and “The Power of Partnering” from Dr. Karen Atkin, Vice President of R&D China, AstraZeneca. According to Dr. Atkin, AstraZeneca has active plans to capitalize on the tremendous growth forecasted for the region. Emerging markets grew at three times the rate of established markets last year and for the next five years, are forecasted to contribute around 70% of pharma growth. In order to take advantage of this growth potential, AstraZeneca has been looking at its R&D strategy and reshaping its business model to add new capabilities and tap into external collaborations and partnerships.

“AstraZeneca is committed to being an active partner in finding creative, collaborative ways to address the most pressing health issues in China and across the globe. We believe that our continued success depends on our ability to build and sustain relationships across the healthcare ecosystem.” – Dr. Karen Atkin, Vice President of R&D China, AstraZeneca

Dr. Samantha Du, CEO, Hutchison MediPharma presented how to Build a World Class Biotech Company in China, describing key factors in constructing a successful R&D company in China. Dr. Du explained how to assemble the best R&D team, how to leverage China resources to set up efficient R&D strategy, how to build a balanced pipeline and most importantly, how to build successful strategic partnerships.

Mr. Matthew Chervenak, CEO, General Biologic offered a keynote address titled, Navigating the China Life Science Landscape. Knowing that China is fast becoming an important player in the life science industry, his address focused on the vital players of the life science industry in China. The importance of knowing who you are doing business with is the key to the success of your company.

“Understanding the potential China value of a drug candidate is essential before engaging deeply in partnership or licensing discussions.” – Mr. Matthew Chervenak, CEO, General Biologic

The last keynote address was given by Mr. William R Keller, GM Deputy, Shanghai Zhangjiang Biotech & Pharmaceutical Base Development, from the largest science park in China. He explained how China's Future Role as a Life Science Leader can assist Western and Chinese companies grow and prosper.

Following the success of BPC, TVG is excited to offer a global network of partnering opportunities in 2011 including BioPartnering North America^TM, BioPartnering India^TM, C21 BioVentures^TM, BioPartnering Latin America^TM and BioPartnering Europe^TM. For more information, please visit: http://www.techvision.com

“The life science industry in China is developing very rapidly. China is seizing the moment and is playing a growing role in global innovation. BioPartnering China has attracted companies from 18 countries, to experience this phenomenon, and to look for new business opportunities. TVG is strongly committed to a long-term presence in China, to facilitate partnering between Chinese life sciences companies and the rest of the world.” – Dr. Robert Lee Kilpatrick, Partner, TVG

About Technology Vision Group

Technology Vision Group LLC (TVG) is the leading networking development organization serving the international life sciences industry. Since 1992, TVG has been developing innovative methods to help life science and associated technology companies attract partners and investors, acquire new products and technologies, and achieve a variety of other strategic business development goals.

About biopartnering.com

biopartnering.com^TM is a unique and powerful internet platform developed by TVG to enhance conference participation before, during and after BPE. biopartnering.com facilitates automated meeting scheduling and includes powerful search tools to help users identify key targets. biopartnering.com also includes time management tools that allow delegates to make the most of their time at the conference and ensure that they capitalize on all the opportunities afforded at BPC.

Producers

Technology Vision Group LLC (TVG) & Shanghai Zhangjiang Biotech & Pharmaceutical Base Development

2010 Podium Presenters (As of December 4, 2010)

Alfama, Inc.; Chipscreen Biosciences, Ltd; Entelos, Inc.; Fate Therapeutics Inc.; Immune Design Inc.; Interprotein Corporation; Invida Group Pte Ltd; MeDiscov Inc.; NovaBay Pharmaceuticals, Inc.; Onyx Pharmaceuticals Inc.; PLx Pharma Inc.; SanBio, Inc.; SciClone Pharmaceuticals, Inc.; Shanghai Medicilon Inc.; Synexa Life Sciences; T-Ray Science, Inc.

Collaborators

BayHelix Group; eChinaChem; European Federation of Biotechnology; General Biologic

Platinum Sponsor

AstraZeneca

Silver Sponsors

Eli Lilly & Co.; Novo Nordisk

Conference Sponsors

Nature Publishing Group

Conference Supporters

AusBiotech

Media Sponsors

Business Wire; Innovaro Pharmalicensing

Media Supporters

BioCentury; Bio-IT World; Biotech East; BioWorld Today; Current Partnering, European Business Review (Samedan Limited); eChinaBio; European Life Science; goBalto; Life Sciences Lab; Nordic Life Science; Pharmatching.com; PharmaVoice

Regional Affiliates

Portuguese Bioindustries Association (APBio); BayHelix Group; BioIndustry Association (BIA); BioFlorida, BioForward, BioNJ; BIOTECanada; Colorado BioScience Association; GeorgiaBio; Indiana Health Industry Forum; Medicon Valley Alliance; Netherlands Biotech Industry (niaba); One Nucleus; Queensland Clincial Trials Network (QCTN); Swiss Biotech Association (SBA)